Literature DB >> 8648210

Prognostic value of viremia in patients with long-standing human immunodeficiency virus infection. Swiss HIV Cohort Study Group.

A Galetto-Lacour1, S Yerly, T V Perneger, C Baumberger, B Hirschel, L Perrin.   

Abstract

Human immunodeficiency virus (HIV) viremia was evaluated in 73 patients with long-standing infection to investigate its relationship with clinical or biologic parameters and to assess its use as a predictor of clinical progression and death. After adjustment for other parameters, baseline HIV RNA level was significantly associated with baseline clinical stage and CD4 cell count. During follow-up (mean, 14.6 months), 16 patients died; 34 others had clinical progression of disease. In multivariate analysis, mortality was better predicted by baseline CD4 cell count (relative hazard [RH] for 100-cell decrease, 3.5; 95% confidence interval [CI], 1.5-8.2; P = .003) than by HIV RNA (P = .28) or clinical stage. HIV RNA level was the best predictor of clinical progression (RH for 1 log increase, 2.8; 95% CI, 1.6-4.9; P < .001). Monitoring of HIV RNA level may help to identify patients who might benefit from antiretroviral or prophylactic therapy.

Entities:  

Mesh:

Substances:

Year:  1996        PMID: 8648210     DOI: 10.1093/infdis/173.6.1388

Source DB:  PubMed          Journal:  J Infect Dis        ISSN: 0022-1899            Impact factor:   5.226


  8 in total

1.  Live, attenuated simian immunodeficiency virus vaccines elicit potent resistance against a challenge with a human immunodeficiency virus type 1 chimeric virus.

Authors:  R Shibata; C Siemon; S C Czajak; R C Desrosiers; M A Martin
Journal:  J Virol       Date:  1997-11       Impact factor: 5.103

2.  Rhesus macaques previously infected with simian/human immunodeficiency virus are protected from vaginal challenge with pathogenic SIVmac239.

Authors:  C J Miller; M B McChesney; X Lü; P J Dailey; C Chutkowski; D Lu; P Brosio; B Roberts; Y Lu
Journal:  J Virol       Date:  1997-03       Impact factor: 5.103

3.  Annotation: wanted--a simple and meaningful HIV staging system.

Authors:  W el-Sadr; J D Neaton
Journal:  Am J Public Health       Date:  1997-04       Impact factor: 9.308

Review 4.  Positive and negative aspects of the human immunodeficiency virus protease: development of inhibitors versus its role in AIDS pathogenesis.

Authors:  K Ikuta; S Suzuki; H Horikoshi; T Mukai; R B Luftig
Journal:  Microbiol Mol Biol Rev       Date:  2000-12       Impact factor: 11.056

5.  Optimization of specimen-handling procedures for accurate quantitation of levels of human immunodeficiency virus RNA in plasma by reverse transcriptase PCR.

Authors:  R E Dickover; S A Herman; K Saddiq; D Wafer; M Dillon; Y J Bryson
Journal:  J Clin Microbiol       Date:  1998-04       Impact factor: 5.948

6.  Mathematical modeling of the interrelationship of CD4 lymphocyte count and viral load changes induced by the protease inhibitor indinavir.

Authors:  G L Drusano; D S Stein
Journal:  Antimicrob Agents Chemother       Date:  1998-02       Impact factor: 5.191

7.  Profound depletion of HIV-1 transcription in patients initiating antiretroviral therapy during acute infection.

Authors:  Adrian Schmid; Sara Gianella; Viktor von Wyl; Karin J Metzner; Alexandra U Scherrer; Barbara Niederöst; Claudia F Althaus; Philip Rieder; Christina Grube; Beda Joos; Rainer Weber; Marek Fischer; Huldrych F Günthard
Journal:  PLoS One       Date:  2010-10-12       Impact factor: 3.240

8.  Cost-effectiveness of HIV screening in patients older than 55 years of age.

Authors:  Gillian D Sanders; Ahmed M Bayoumi; Mark Holodniy; Douglas K Owens
Journal:  Ann Intern Med       Date:  2008-06-17       Impact factor: 25.391

  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.